Company: AZN
Filing Date: 2025-10-20
Form Type: 6-K
Source: 0001654954-25-011943
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-10-20
Form: 6-K
Chunk 5
---
 erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis . 2023;82(3):351-356.

7. Bruce IN, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74:1706-1713.

8. Guéry JC. Why is systemic lupus erythematosus more common in women?. Joint Bone Spine . 2019;86(3):297-299.

9. American College of Rheumatology. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus (SLE). Available at: sle-guideline-summary-2025.pdf . [Last accessed: October 2025].

10. Fanouriakis A, et al . EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis . 2024;83:15-29.

11. Kaul A, et al. Systemic lupus erythematosus. Nat Rev Dis Primers . 2016;2:16039.

12. Barber MRW, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheuatol. 2021;17(9):515-532.

13. Apostolopoulos D and Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017;56(Suppl 1):i114-22.

14. Ji L, et al. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology . 2021;60:5517-26.

15. Lateef A and Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther . 2012;14(Suppl 4):S4.

16. AstraZeneca data on file. REF-291165. 2025

17. AstraZeneca data on file. REF-290598. 2025.

18. Murimi-Worstell IB, et al. Association between organ damage and